Pfizer Hits 52-Week Low Amid Broader Pharmaceuticals Sector Decline

Pfizer has experienced significant activity today, reaching a new 52-week low of Rs. 3742.9. The stock has been on a downward trend, losing 5.36% over the past two days, with an opening loss of 2.36% today. Intraday, it touched a low of Rs. 3742.9, reflecting a decline of 6.22%. Currently, Pfizer is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish technical outlook.
In the broader market context, the Pharmaceuticals & Drugs sector has also seen a decline of 3.32%. The Sensex, after a gap down opening, has shown some recovery but remains 3.51% away from its own 52-week low. Over the past year, Pfizer's performance has been notably poor, with a return of -11.41%, contrasting sharply with the Sensex's decline of just 1.96%.

Financial metrics reveal that Pfizer's net sales have grown at a mere annual rate of 0.46% over the last five years, while operating profit has increased by 4.27%. The company's return on equity stands at 16.4, but it is considered expensive with a price-to-book value of 4.9, trading at a premium compared to its peers.